News

Apr 15

20MED THERAPEUTICS PUBLISHES POSITIVE IN VIVO EFFICACY DATA OF A MRNA INFLUENZA VACCINE USING ITS PROPRIETARY POLYMERIC NANOPARTICLE TECHNOLOGY

Preclinical data underscores the potential to deliver a strong protective effect using Polymeric Nanoparticles (PNPs), an alternative to...

Feb 2, 2023

20Med Therapeutics and CEPI Sign Agreement to Advance ThermoStable Vaccines Technology

CEPI to initially provide up to USD850,000 to 20Med to advance development of 20Med’s bioresponsive polymeric nanoparticle platform for...

Jun 1, 2021

20Med Therapeutics started research into mRNA vaccines against variants of the SARS-CoV-2 virus

The SARS-CoV-2 pandemic has shown the need to be prepared for an outbreak of an infectious disease. It spurred one of the most promising...